Rose Beck YOU? Author Swipe

Last 10y

Clinical validation of the Lilly SP‐X P‐tau217 assay: Performance in underrepresented cohorts Open

Michael E. Hodsdon, Adam Abel, Antonio Chambers, Ming‐Chi Lu, Amanda Sheffield Morris , et al. · 2025

INRODUCTION Plasma phosphorylated tau217 (p‐tau217) is a biomarker for the detection of amyloid pathology. We present performance characteristics of the Lilly SP‐X P‐tau217 assay in a clinical validation cohort, as a whole and divided into…

Analytical Validation and Performance of a Blood-Based P-tau217 Diagnostic Test for Alzheimer Disease Open

Adam Abel, Antonio Chambers, Jeff A. Fill, Heinz Reiske, Ming‐Chi Lu , et al. · 2025

Background Blood-based biomarkers, especially P-tau217, have been gaining interest as diagnostic tools to measure Alzheimer disease (AD) pathology. Methods We developed a plasma P-tau217 chemiluminescent immunoassay using 4G10E2 and IBA493…

Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT) Open

Michael E. Hodsdon, Adam Abel, Antonio Chambers, Ming‐Chi Lu, Amanda Sheffield Morris , et al. · 2024

Background Blood‐based biomarkers have significant potential to aid in the diagnosis of Alzheimer’s disease (AD), providing a more accessible option than cerebrospinal fluid testing or positron emission tomography (PET). This study evaluat…

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C) Open

Jeremy S. Abramson, David J. Straus, Nancy L. Bartlett, John M. Burke, Ryan C. Lynch , et al. · 2023

Introduction Brentuximab vedotin (BV) with AVD is approved in classical Hodgkin lymphoma (cHL) and has demonstrated statistically significant improvement in 6-year overall survival (OS) as compared with ABVD; associated neuropathy and neut…

Figure 2S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 2 BAFF induces up-regulation of survival pathways. A, PT-3 ALL cells were cultured with VAY736 (20 ÃŽÂ¼g/mL) and recombinant BAFF (0.2 ÃŽÂ¼g/mL) for 72 hours and the expression levels of proliferation genes (p100, p52) and survi…

Figure 4S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 4 Detection of NK cells in vivo A, Representative Dot plots of gated live cells based on FSCÃ,ÂA and SSCÃ,ÂA and CD19+CD10+ cells in the bone marrow and spleen of NSG mice treated with PBS (left) or 2x106 PTÃ,Â3 ALL cells (ri…

Figure 1S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 1 ALL sample characteristics. A, Summary data from 11 adults and 5 pediatric ALL patients. Genetic and diagnostic information was provided by clinical pathologist Rose Beck at University Hospitals Medical Center (UHMC). BAFF-R e…

Figure 3S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 3 Differential NK cells receptor expression A, Expression of activating and inhibitory receptors in NK cells expanded from the indicated healthy donors (mean {plus minus} SD of 3 technical replicates). B, Expression of HLAE and …

Figure 1S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 1 ALL sample characteristics. A, Summary data from 11 adults and 5 pediatric ALL patients. Genetic and diagnostic information was provided by clinical pathologist Rose Beck at University Hospitals Medical Center (UHMC). BAFF-R e…

Data from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Drug-resistant acute lymphoblastic leukemia (ALL) patients do not respond to standard chemotherapy, and an urgent need exists to develop new treatment strategies. Our study exploited the presence of B-cell activating factor receptor (BAFF-…

Figure 6S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 6 EW-7197 treatment increases VAY736 induced NK cell mediated ADCC of ALL cells in vivo A, Percentages of CD16+ NK cells in bone marrow and spleen of mice from Figure.6C-E. B, Normalized weight in grams (spleen weight/mouse weig…

Figure 5S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 5 EW-7197 treatment increases VAY736 induced NK cell mediated ADCC of ALL cells in vivo A, Mouse TGF-beta Elisa using serum from PBS or ALL (PT-3) i.v. injected mice on day 35. B, Normalized weight (spleen weight/mouse weight) a…

Supplementary Figure Legends from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supplementary Figure Legends

Figure 4S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 4 Detection of NK cells in vivo A, Representative Dot plots of gated live cells based on FSCÃ,ÂA and SSCÃ,ÂA and CD19+CD10+ cells in the bone marrow and spleen of NSG mice treated with PBS (left) or 2x106 PTÃ,Â3 ALL cells (ri…

Figure 5S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 5 EW-7197 treatment increases VAY736 induced NK cell mediated ADCC of ALL cells in vivo A, Mouse TGF-beta Elisa using serum from PBS or ALL (PT-3) i.v. injected mice on day 35. B, Normalized weight (spleen weight/mouse weight) a…

Supplementary Figure Legends from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supplementary Figure Legends

Figure 3S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 3 Differential NK cells receptor expression A, Expression of activating and inhibitory receptors in NK cells expanded from the indicated healthy donors (mean {plus minus} SD of 3 technical replicates). B, Expression of HLAE and …

Figure 6S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 6 EW-7197 treatment increases VAY736 induced NK cell mediated ADCC of ALL cells in vivo A, Percentages of CD16+ NK cells in bone marrow and spleen of mice from Figure.6C-E. B, Normalized weight in grams (spleen weight/mouse weig…

Data from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Drug-resistant acute lymphoblastic leukemia (ALL) patients do not respond to standard chemotherapy, and an urgent need exists to develop new treatment strategies. Our study exploited the presence of B-cell activating factor receptor (BAFF-…

Figure 2S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 2 BAFF induces up-regulation of survival pathways. A, PT-3 ALL cells were cultured with VAY736 (20 ÃŽÂ¼g/mL) and recombinant BAFF (0.2 ÃŽÂ¼g/mL) for 72 hours and the expression levels of proliferation genes (p100, p52) and survi…

Data from Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function Open

Weihuan Wang, Grant Zimmerman, Xiaoran Huang, Shuiliang Yu, Jay Myers , et al. · 2023

More than half of T-cell acute lymphoblastic leukemia (T-ALL) patients harbor gain-of-function mutations in the intracellular domain of Notch1. Diffuse infiltration of the bone marrow commonly occurs in T-ALL and relapsed B-cell acu…

Supplemental Figure Legends from Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function Open

Weihuan Wang, Grant Zimmerman, Xiaoran Huang, Shuiliang Yu, Jay Myers , et al. · 2023

Supplemental Figure Legends

Supplemental Information from Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function Open

Weihuan Wang, Grant Zimmerman, Xiaoran Huang, Shuiliang Yu, Jay Myers , et al. · 2023

Supplemental Materials and Methods This file contains detailed methods of IHC, WB, CHIP assay, luciferase reporter assay, qRT-PCR and 2-photon imaging analysis and etc.

Data from Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function Open

Weihuan Wang, Grant Zimmerman, Xiaoran Huang, Shuiliang Yu, Jay Myers , et al. · 2023

More than half of T-cell acute lymphoblastic leukemia (T-ALL) patients harbor gain-of-function mutations in the intracellular domain of Notch1. Diffuse infiltration of the bone marrow commonly occurs in T-ALL and relapsed B-cell acu…

Supplemental Information from Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function Open

Weihuan Wang, Grant Zimmerman, Xiaoran Huang, Shuiliang Yu, Jay Myers , et al. · 2023

Supplemental Materials and Methods This file contains detailed methods of IHC, WB, CHIP assay, luciferase reporter assay, qRT-PCR and 2-photon imaging analysis and etc.

Supplemental Figures from Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function Open

Weihuan Wang, Grant Zimmerman, Xiaoran Huang, Shuiliang Yu, Jay Myers , et al. · 2023

Supplemental Figures. This file contains supplemental figures concerning analysis of megakaryocyte progenitor and erythroid progenitor analysis in the leukemia marrow, platelet and megakaryocyte progenitor analysis after DBZ treatment of l…

Supplemental Figure Legends from Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function Open

Weihuan Wang, Grant Zimmerman, Xiaoran Huang, Shuiliang Yu, Jay Myers , et al. · 2023

Supplemental Figure Legends

Supplemental Figures from Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function Open

Weihuan Wang, Grant Zimmerman, Xiaoran Huang, Shuiliang Yu, Jay Myers , et al. · 2023

Supplemental Figures. This file contains supplemental figures concerning analysis of megakaryocyte progenitor and erythroid progenitor analysis in the leukemia marrow, platelet and megakaryocyte progenitor analysis after DBZ treatment of l…

Obesity accelerates acute promyelocytic leukemia in mice and reduces sex differences in latency and penetrance Open

John W. R. Kincaid, Gretchen Weiss, Anne E. Hill‐Baskin, Heidi M. Schmidt, Ovwoioise Omoijuanfo , et al. · 2022

Objective Obesity has emerged as a prominent risk factor for multiple serious disease states, including a variety of cancers, and is increasingly recognized as a primary contributor to preventable cancer risk. However, few studies of leuke…

Endothelial PERK-ATF4-JAG1 axis activated by T-ALL remodels bone marrow vascular niche Open

Cui Liu, Qiuyun Chen, Yinghui Shang, Lechuang Chen, Jay Myers , et al. · 2022

The endoplasmic reticulum unfolded protein response (UPR) is a conserved adaptive signaling in ER homeostasis and has emerged as critical in highly proliferating cells and potential treatment target for acute T-cell lymphoblastic leukemia …

Fetching topic information...